Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Analyst Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
COGT Stock 12 Month Forecast
Average Price Target
$15.75
▲(118.14%Upside)
| Highest Price Target$25.00 | Average Price Target$15.75 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$15
Buy
107.76%
Upside
Initiated
06/30/25
LifeSci Capital
$16
Buy
121.61%
Upside
Reiterated
06/30/25
Piper Sandler
$24
Buy
232.41%
Upside
Reiterated
06/25/25
Leerink Partners
―
Buy
―
Reiterated
06/18/25
We hosted a dinner with two indolent systemic mastocytosis (ISM) KOLs, one of whom is an allergist and one of whom is a hematologist oncologist at large tertiary referral centers. Most importantly, the KOLs see room for an second agent in ISM, initiallly driven by the ~20-30% of addressable patients with high symptom burden that are not adequately controlled by BPMC's (MP) Ayvakit. While Ayvakit rarely induces robust symptom control at the labeled 25 mg dose, both KOLs are escalating to 50mg in the majority of their patients, with one of the KOL's starting all patients at 50 mg in his practice. These algorithms provide adequate disease control in ~70-80% of the addressable ISM population, with the remainder thought to be beneficiaries of a drug with higher efficacy.
Needham
―
Hold
―
Reiterated
06/17/25
J.P. Morgan
$21→$25
Buy
246.26%
Upside
Reiterated
05/29/25
H.C. Wainwright
$14→$12
Buy
66.20%
Upside
Reiterated
05/20/25
Scotiabank
$17
Buy
135.46%
Upside
Reiterated
05/07/25
Robert W. Baird
$8→$7
Hold
-3.05%
Downside
Reiterated
05/07/25
Jefferies
$20
Buy
177.01%
Upside
Reiterated
02/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$15
Buy
107.76%
Upside
Initiated
06/30/25
LifeSci Capital
$16
Buy
121.61%
Upside
Reiterated
06/30/25
Piper Sandler
$24
Buy
232.41%
Upside
Reiterated
06/25/25
Leerink Partners
―
Buy
―
Reiterated
06/18/25
We hosted a dinner with two indolent systemic mastocytosis (ISM) KOLs, one of whom is an allergist and one of whom is a hematologist oncologist at large tertiary referral centers. Most importantly, the KOLs see room for an second agent in ISM, initiallly driven by the ~20-30% of addressable patients with high symptom burden that are not adequately controlled by BPMC's (MP) Ayvakit. While Ayvakit rarely induces robust symptom control at the labeled 25 mg dose, both KOLs are escalating to 50mg in the majority of their patients, with one of the KOL's starting all patients at 50 mg in his practice. These algorithms provide adequate disease control in ~70-80% of the addressable ISM population, with the remainder thought to be beneficiaries of a drug with higher efficacy.
Needham
―
Hold
―
Reiterated
06/17/25
J.P. Morgan
$21→$25
Buy
246.26%
Upside
Reiterated
05/29/25
H.C. Wainwright
$14→$12
Buy
66.20%
Upside
Reiterated
05/20/25
Scotiabank
$17
Buy
135.46%
Upside
Reiterated
05/07/25
Robert W. Baird
$8→$7
Hold
-3.05%
Downside
Reiterated
05/07/25
Jefferies
$20
Buy
177.01%
Upside
Reiterated
02/25/25
Best Analysts Covering Cogent Biosciences
1 Month
xxx
Success Rate
14/28 ratings generated profit
Average Return
+3.14%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.14% per trade.
3 Months
xxx
Success Rate
5/10 ratings generated profit
Average Return
-0.39%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.39% per trade.
1 Year
Success Rate
5/10 ratings generated profit
Average Return
-2.32%
reiterated a buy rating 16 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.32% per trade.
2 Years
xxx
Success Rate
10/28 ratings generated profit
Average Return
-4.24%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of -4.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
COGT Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
May 25
Jun 25
Strong Buy
11
11
9
13
13
Buy
3
0
0
0
1
Hold
2
5
3
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
16
12
18
18
Each month's total comprises the sum of three months' worth of ratings.
COGT Financial Forecast
COGT Stock Forecast FAQ
What is COGT’s average 12-month price target, according to analysts?
Based on analyst ratings, Cogent Biosciences’s 12-month average price target is 15.75.
What is COGT’s upside potential, based on the analysts’ average price target?
Cogent Biosciences has 118.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is COGT a Buy, Sell or Hold?
Cogent Biosciences has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
What is Cogent Biosciences’s price target?
The average price target for Cogent Biosciences is 15.75. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 118.14% Increase from the current price of $7.22.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 118.14% Increase from the current price of $7.22.
What do analysts say about Cogent Biosciences?
Cogent Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of COGT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.